The Trust (irrevocable, >$5M assets, Rahul as both trustee and beneficiary) commits $100K to Sponic Gardens, Inc. and ends up owning roughly 1/3 of the common stock (rough parity with Sonia and Rahul individually). This doc walks through: why a SAFE is the wrong instrument for this specific goal, the three viable mechanics for a Direct Common Stock investment, the §1202 QSBS analysis that drives the recommendation, the self-dealing process that keeps the transaction defensible, how this plays with future external SAFE investors, and step-by-step execution. Companion to the formation playbook and the 409A decisioning doc.
Issue 4,000,000 shares of common stock to the Trust at $0.025/share ($100K total) via a single Stock Purchase Agreement on Day 1, with payment in tranches against a Promissory Note for the unpaid balance. All 4M shares issued immediately — that starts the §1202 QSBS five-year holding clock on all of them simultaneously, the largest single financial benefit available in this transaction (potentially $10M+ federal tax exclusion at exit). Trust pays first tranche (e.g., $25K) at signing; promissory note covers the remaining $75K, secured by the issued shares with company repurchase rights on default. Sonia votes as the disinterested director authorizing the issuance; Rahul recuses on the company side and documents the trust-side fiduciary process in a separate trustee memorandum. Form D filed with SEC within 15 days; state blue-sky notice filings as applicable to trust's state of formation. Skip SAFE entirely for this case — SAFEs convert to preferred (or require non-standard drafting to convert to common), defer the §1202 holding clock, and don't deliver the immediate 1/3 ownership the goal requires.
The instinct to reach for a SAFE is right for most early-stage investments — they're standard, fast, and defer the valuation question. But three of Sponic's specific facts make SAFE a bad fit here:
| SAFE problem | Why it bites Sponic |
|---|---|
| Standard YC SAFE converts to preferred at the next priced round | Exactly what we want to avoid. Forcing it to convert to common requires custom drafting, which is non-standard and will raise questions in future investor diligence ("what is this and why does it convert weirdly?"). |
| SAFE doesn't grant equity until conversion | "Trust owns ~1/3" is the explicit goal Day 1. A SAFE that may sit unconverted for years (no priced round on the calendar) doesn't deliver this. Trust would have no voting rights, no formal stake, and would not appear as a common holder on the cap table. |
| §1202 QSBS holding period doesn't start until SAFE converts to actual stock | This is the financial dealbreaker. §1202 lets a non-corporate holder (incl. trusts) exclude up to $10M or 10× basis in federal cap-gains at exit on stock held for 5+ years. Starting the clock 5 years from now (Direct Common) vs. starting it from "whenever the SAFE converts at some future priced round" can mean the difference between excluding $1M+ of gain and excluding nothing. On a successful exit, this exclusion alone can be worth more than the entire $100K investment. |
The fourth and softer reason: SAFEs are designed for arm's-length outside money. Using one for a related-party insider investment is procedurally weird — a SAFE postpones the "what's this worth?" question, but the IRS and a future investor will both look at a related-party SAFE and ask the question anyway. Better to handle the pricing analysis cleanly up front, with a properly-documented disinterested-director approval, than to defer it into a setup that looks like obfuscation.
The Trust Investment is just a stock purchase. Treat it like one.
Three ways to structure a Direct Common Stock investment from the Trust. Pick one; the rest of the doc assumes Mechanic 1 (the recommendation).
How it works: Trust signs a Stock Purchase Agreement for all 4,000,000 shares at $0.025/share ($100K total). Pays first tranche (e.g., $25K) at signing. Issues a promissory note to Sponic for the unpaid $75K, secured by the issued shares with a company repurchase right if the note defaults. All 4M shares are issued to the Trust immediately and appear in the stock ledger Day 1.
Why it wins:
Trade-off: if Trust were to default on the promissory note, Sponic must exercise the repurchase right and cancel unpaid shares — adds a procedural step. With Rahul as trustee of a $5M+ trust and a strong economic interest in the success, default risk is essentially zero.
How it works: Trust signs a Subscription Agreement committing to purchase 4M shares at $0.025/share. Each $25K tranche triggers: a separate board consent, a separate stock issuance, and a separate certificate for ~1M shares. The Trust appears on the cap table tranche-by-tranche.
Why it's simpler: no promissory note, no default mechanics. Each tranche is a clean, complete, paid-in-full stock sale.
Why it costs more in the long run: the §1202 5-year clock starts independently on each tranche. Tranche 1 → Month 0. Tranche 4 → Month 12. If exit happens at Month 54 (4.5 years), tranches 2–4 don't qualify for §1202. Estimated cost of fragmentation on a successful exit: ~75% of the §1202 benefit lost.
When to consider: only if you specifically want to avoid any promissory-note paperwork AND are willing to give up most of the §1202 benefit.
How it works: Trust loans $100K to Sponic via a promissory note that converts to common at $0.025/share as each tranche is advanced. Effectively Mechanic 1 with extra accounting steps (debt on the balance sheet until conversion).
Why not: adds accounting complexity, possible interest-imputation issues if rates are below the Applicable Federal Rate, no benefit over Mechanic 1. Skip.
| Dimension | Mechanic 1 — Full Issuance + Note | Mechanic 2 — Pay-as-You-Go | SAFE (standard, → preferred) | SAFE (custom, → common) |
|---|---|---|---|---|
| Trust owns 4M shares Day 1 | ✅ | ⚠ Only first tranche | ❌ | ❌ |
| §1202 5-yr clock starts now on all 4M | ✅ | ⚠ Only first tranche | ❌ | ❌ |
| Standard / battle-tested documents | ✅ SPA + note | ✅ Subscription | ✅ YC SAFE | ❌ Custom drafting |
| Anchors common FMV at $0.025/share | ⚠ Yes | ⚠ Yes | ✅ No anchor | ⚠ Partial (via cap) |
| External SAFE investors comfortable | ✅ Trust = common holder | ✅ | ⚠ Insider preferred ahead of them | ❌ Raises diligence questions |
| Voting rights for Trust | ✅ Yes | ⚠ Per tranche | ❌ None | ❌ None until conversion |
| Self-dealing scrutiny manageable | ⚠ Higher — pricing a stock sale to insider entity | ⚠ Same as Mech 1 | ⚠ Defers but doesn't eliminate | ⚠ Cap is a quasi-price |
| Number of corporate actions to issue $100K | 1 | 4 (one per tranche) | 1 | 1 |
| Clerky tooling supports it natively | ✅ (SPA + note via Lifetime) | ✅ (SPA per tranche) | ✅ (SAFE library) | ❌ Custom |
Section 1202 of the Internal Revenue Code lets a non-corporate holder (individual, trust, estate, partnership) exclude up to the greater of $10M or 10× basis of federal capital-gains tax on the sale of "qualified small business stock" (QSBS) held for at least 5 years. For an irrevocable trust like ours, this benefit flows to the trust (which can then distribute the after-tax proceeds to beneficiaries per the trust's terms).
Suppose Sponic exits at $30M total, Trust holds ~33% = $10M of the gain. With QSBS held 5+ years:
For a smaller exit (e.g. $5M total, Trust takes ~$1.65M): the entire gain is excluded, saving ~$390K federal tax.
Even for a modest exit, the §1202 benefit dwarfs the $100K investment. This is why we issue Day 1 and start the clock now.
The one real cost of Mechanic 1 is that the Trust's purchase establishes the common stock FMV at $0.025/share going forward. Future option grants within 12 months must have a strike price at least $0.025/share unless a separate 409A explicitly justifies a lower number (which would be hard to defend after a recent arm's-length sale at $0.025).
In practice this is a small cost:
The 409A decisioning doc previously flagged "Trust takes direct common" as not recommended precisely because of this FMV anchor. That recommendation is superseded by this doc. Given the §1202 benefit's magnitude (~$2M federal tax saved on a $10M Trust gain), the FMV anchor is a smaller cost worth accepting. The 409A doc is updated to reflect the new recommendation; Stage 2-alt there now points back here.
The Trust's governing instrument permits self-dealing (one of the user-provided premises). That's the legal authority. The process is what makes it actually defensible if anyone — IRS, a future investor, a future trust beneficiary — challenges the transaction. Five elements:
The Sponic board (Sonia + Rahul) approves the issuance via written consent. Rahul recuses on the vote, citing his role as trustee of the purchaser. Sonia votes alone as the disinterested director. Consent explicitly records: the recusal, the disinterested vote, the determination that $0.025/share is fair value, and the authorization to issue 4,000,000 shares to the Trust.
The board consent attaches (or references) a brief written rationale for the $0.025/share price. It doesn't have to be a full 409A appraisal — a 1-page memo is enough. Sample content: "the company is pre-revenue and pre-product; founders bought at par ($0.00001/share); the company has since [list any value-creating events — IP, prototypes, signed letters of intent, etc.]; a price of $0.025/share reflects a 2,500× step-up from par appropriate to outside (non-founder) capital at the company's current stage, while remaining well below any plausible third-party investor price." This rationale lives in the corporate records permanently.
Rahul, in his capacity as trustee, signs a separate memo to the trust file documenting his fiduciary process: trust governing instrument cited (Section X permits investments in private securities and self-dealing); conflict-of-interest acknowledged (trustee is also director of issuer); investment evaluated for trust beneficiaries based on stated criteria (e.g., expected return profile, diversification, illiquidity tolerance); conclusion that the investment is in the trust's interests. This memo stays in the trust's records, not Sponic's.
Form D filed with the SEC within 15 days of first sale identifies the Trust by name as the purchaser. Public record; no concealment. Filing fee: $0.
The Trust transaction appears in the data room shown to any future SAFE investor. The cap table shows the Trust as a common holder. Investors who care will ask about the related-party nature; the answer is the disinterested-director process above. Done correctly, this is not a deal-killer — investors regularly see founder-friendly insider equity, and a transparent, well-documented Trust investment is much easier to swallow than an opaque one discovered mid-diligence.
Future external SAFE investors will come in, eventually convert to preferred at a priced round, and want to know how the Trust transaction interacts with their interests. Direct Common gets this right by default:
| External-investor concern | How Direct Common addresses it |
|---|---|
| "Is there preferred ahead of me?" | No. Trust holds common, same as founders. External SAFE converts to Series Seed Preferred at the priced round and sits at the top of the liquidation waterfall. |
| "Does the Trust have anti-dilution / pro-rata / information rights?" | No (recommended). Trust is a common holder; gets exactly what bylaws + DGCL grant common stockholders. No side letter. Trust effectively gets information via Rahul's board seat, not via a formal investor-rights letter. |
| "Is this a real arm's-length investment or a paper transaction?" | Real — $100K cash actually moves into Sponic, in tranches per a binding agreement. Form D is filed. Promissory note is enforceable. Disinterested-director approval documented. |
| "What pre-money valuation does this imply, and will I be expected to invest at a similar price?" | The Trust transaction implies a pre-money of ~$200K (founders at 8M × $0.025 = $200K). External SAFE investors set their own cap independently; the Trust transaction is a data point, not a constraint. The 12-month gap between Trust investment and external SAFE is usually enough that "market has moved" is a credible explanation for a higher cap. |
| "Will the Trust block the next round?" | No. Trust as a common holder has only the voting rights of any common stockholder. Standard protective provisions for the Series Seed Preferred (when SAFEs convert) won't be controlled by the Trust. |
The one external-investor question to be ready for: "Why isn't this just a SAFE?" Answer prepared: "We wanted to capture §1202 from Day 1, the goal was three-way ownership parity rather than deferred conversion, and we ran a clean disinterested-director process to set the price." This is a defensible answer; most investors will move on.
| Filing | When | Cost | What it does |
|---|---|---|---|
| SEC Form D (Rule 506(b) exemption) | Within 15 days of first stock issuance to the Trust | $0 | Notice filing claiming the Rule 506(b) private-placement exemption from registration. Trust must be an accredited investor (confirmed: >$5M assets satisfies the institutional-accredited test). |
| State blue-sky notice filings | Per the trust's state of formation + Sponic's state of formation (Delaware) | $0–200 | Most states require notice filings parallel to Form D under the National Securities Markets Improvement Act (NSMIA). DE waives for issuers; TX and HI have light notice-filing requirements. Confirm with trust counsel which state laws apply. Typically $50–200 per state. |
| 83(b) election for Trust? | Not applicable | $0 | §83(b) elections are for service providers receiving stock subject to vesting. The Trust is an investor, not a service provider; no §83(b) needed. (Confirm: the Trust's stock is not subject to forfeiture or vesting based on services — the only constraint is the company's repurchase right on default of the promissory note, which is a different mechanism.) |
Assumes Sponic Gardens, Inc. is already formed via Clerky (see formation playbook) and the founders have completed their RSPAs + 83(b) elections. The Trust transaction happens as a separate corporate action after formation.
Trust side: Rahul-as-trustee reviews the trust governing instrument to confirm authority to make this investment (private security, related-party). Drafts the trustee fiduciary memorandum (§8 element 3 above) and signs it before the transaction.
Company side: board (Sonia + Rahul) discusses and agrees on the $0.025/share price. Sonia drafts the contemporaneous fair-value rationale (§8 element 2 above) as a 1-page memo for the corporate records.
Confirm accredited-investor status: Trust qualifies as accredited via the >$5M assets test (Rule 501(a)(7)). Document the basis (asset summary, trust formation date confirming >6 months old, etc.) in case asked.
Use Clerky's transactional library (free under Lifetime; ~$29/document under Pay Per Use):
Trust wires $25K to Sponic's Mercury account. Booked as "Common stock issuance — Trust, tranche 1 of 4". §1202 holding period clock starts on all 4M shares from this date (the date of stock issuance, not the date of full payment).
Online filing via SEC EDGAR. Free. Identifies Sponic as the issuer, the Trust as the purchaser, $100K as the offering amount, Rule 506(b) as the claimed exemption. Takes ~30 minutes for first filing (longer because you have to set up the EDGAR filer codes); subsequent filings are faster.
Identify the states where notice filing is required: Delaware (issuer's state — usually waived for de-minimis offerings under NSMIA), the Trust's state of formation (TX or HI — confirm), and any state where the Trust has a "place of business" that triggers a separate filing. Each state's notice form + fee. Total typically $50–400.
Trust wires each $25K tranche per the schedule. Sponic's bookkeeping books each as "Promissory note principal payment — Trust". The promissory note is amortized; when fully paid, the pledge is released and the note is marked satisfied.
The Trust transaction shows up in: Sponic's Form 1120 (no impact on income; common-stock issuance is a balance-sheet event), the cap table, the §1202 tracking (5-year clock noted in stock ledger). Trust receives no K-1, no 1099-DIV (no dividends), no taxable event from the issuance itself.
| Risk | Likelihood | Mitigation |
|---|---|---|
| Trust defaults on the promissory note | Very low (Trust is >$5M assets, Rahul beneficiary) | Repurchase right in the Pledge Agreement; Sponic cancels unpaid shares at $0 cost. Cleanup is procedural, not financial. |
| IRS challenges the $0.025/share price as below FMV (treating spread as a deemed gift or compensation) | Low — contemporaneous rationale + disinterested-director process | Document the price rationale at the time (§8 element 2). At Sponic's pre-revenue stage, $0.025/share is defensible. If challenged, the worst case is the company recharacterizes the discount as additional compensation to Rahul; would owe back tax on a tiny amount. |
| Future investor objects to the related-party transaction | Moderate — but manageable | Transparency in the data room; the disinterested-director process and Form D filing demonstrate arm's-length compliance. Most investors accept a well-papered Trust investment. |
| §1202 disqualified by a future redemption | Low — but real if we ever buy back founder stock | Before any stock repurchase, check §1202 redemption rules. There's a 2-year "tainted period" around any redemption that can disqualify QSBS issued in that window. |
| FMV anchor causes early option grants to have a higher strike than ideal | Certain — by design | $0.025/share strike is still extremely low in absolute terms. Use phantom equity (per 409A doc §6) for advisor-class grants where strike matters; use real options + 409A when the recipient genuinely needs ISOs. |
| Trust's governing instrument is narrower than assumed | Should be confirmed before signing | Rahul reviews the trust instrument and confirms self-dealing + private-security investments are permitted. If not, this whole structure needs to revisit. |
| Trust's state of formation (TX vs HI) affects blue-sky filings or state tax exclusion | Material to logistics, not to the decision | Confirm trust's state of formation before §11 step 6. Update state-filing checklist accordingly. |
| Trust accreditation challenged | Very low (>$5M assets is well above the $5M threshold) | Keep documentation of trust assets and formation date as part of corporate records. |